Fluorescence imaging device receives FDA De Novo clearance

21st August 2018
Posted By : Enaie Azambuja
Fluorescence imaging device receives FDA De Novo clearance

MolecuLight has achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X. The device digitally captures and documents fluorescence information from wounds and surrounding tissue using still images and videos in real-time. This product is optimised for use at the point-of-care. It is compact and portable, with no requirement to use contrast agents.

“The MolecuLight i:X platform is a significant advancement in the management of chronic wounds, that is already revolutionising wound care practice in Canada and Europe” said Dr. Ralph DaCosta, Founder, Chief Scientific Officer and Director of MolecuLight.

“Thousands of patients to date have already experienced a change in their assessment and treatment by clinicians who feel empowered by the wound fluorescence images they are seeing".

"As reported in multi-centered published clinical studies, clinicians used the images to inform their wound management practices in real-time, in particular, for guided wound sampling, cleaning and debridement. We’re very excited that US clinicians will soon have the same access to this device as their peers in Canada and Europe.’’

“FDA marketing authorisation of the MolecuLight i:X is a monumental milestone for the wound care industry” said Anil Amlani, CEO of MolecuLight Inc. “Thanks to continued clinical studies and 17 publications to date, the clinical evidence is rapidly accumulating that the MolecuLight i:X is a must‑have device in the hands of all wound care clinicians.’’

In the US, the MolecuLight i:X is indicated as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds at the point of care, to (i) view and digitally record images of a wound, and (ii) view and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. The MolecuLight i:X is for prescription use only.

The MolecuLight i:X received Health Canada Medical Device License in 2015 and European CE Mark in 2016.


You must be logged in to comment

Write a comment

No comments




More from MolecuLight

Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

Maintec 2018
6th November 2018
United Kingdom NEC, Birmingham
electronica 2018
13th November 2018
Germany Messe Munchen
SPS IPC Drives 2018
27th November 2018
Germany Nuremberg
International Security Expo 2018
28th November 2018
United Kingdom London Olympia
The Security Event 2019
9th April 2019
United Kingdom NEC, Birmingham